Finasteride (Proscar), which inhibits conversion of testosterone to the more potent androgen dihydrotestosterone, reduces symptoms of benign prostatic hyperplasia (BPH). Because androgens promote the ...
The 24.8% relative risk reduction in prostate cancer seen in the finasteride arm prompted the early termination of the study on February 21, 2003, 15 months before its anticipated completion. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results